We use cookies to help provide you with the best possible online experience.
By using this site, you agree that we may store and access cookies on your device. Cookie policy.
Cookie settings.
Functional Cookies
Functional Cookies are enabled by default at all times so that we can save your preferences for cookie settings and ensure site works and delivers best experience.
3rd Party Cookies
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Respiratory syncytial virus (RSV)
Respiratory syncytial virus (RSV) is a major respiratory virus that is common over the winter period, typically November to February.
The RSV (Respiratory Syncytial Virus) vaccine is an important preventative measure aimed at protecting those most at risk, particularly adults aged 75 and older, those 65 and over with certain underlying health conditions, and pregnant women.
This vaccine helps reduce the risk of severe respiratory illness by stimulating the immune system to defend against RSV.
We will start to invite those eligible in due course. This will be starting oldest first (pregnant women will be called separately from 28 weeks), and invites for these patients will be going out until August 2025
Updated 14th January 2025
Published: Aug 19, 2024